HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis
NCT01847248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118
Last updated 2013-11-25
Summary
* Molecules indicating endothelial injury may serve as biomarkers for severe sepsis because of the critical role of endothelial injury in organ dysfunction during severe sepsis.
* HSPA12B is primarily located in endothelial cells and detectable during sepsis.
* The investigators speculated that HSPA12B from endothelial cells might be correlated with severe sepsis.
Conditions
Sponsors & Collaborators
-
Changhai Hospital
lead OTHER
Principal Investigators
-
Ke-ming Zhu, M.D. · Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-05-31
- Primary Completion
- 2013-03-31
- Completion
- 2013-10-31
Countries
- China
Study Locations
More Related Trials
-
Identification of Markers of Poor Clinical Prognosis in Sepsis by Epigenetic Analysis
NCT06446947 ·Status: RECRUITING
-
Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis
NCT01998139 ·Status: COMPLETED
-
STUDY00015328: Sepsis Endotypes
NCT03146546 ·Status: ENROLLING_BY_INVITATION
-
IMproved PREdiction of Severe Sepsis in the Emergency Department
NCT01392508 ·Status: COMPLETED
-
Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients
NCT05911711 ·Status: UNKNOWN
-
Novel Biomarkers Related Xuebijing Injection Improves Sepsis
NCT06920420 ·Status: NOT_YET_RECRUITING
-
Heparin Binding Protein as a Prognostic Biomarker of Sepsis Severity
NCT05610020 ·Status: COMPLETED
-
Establishment of Early Diagnosis and Monitoring Model for Sepsis Patients
NCT04974411 ·Status: UNKNOWN
-
We Collected Blood Samples From Septic Shock Patients and Measured ELABELA, Creatinine, and NGAL Levels. Survival After 7 Days Was Recorded and Analyzed to Evaluate the Potential of Serum ELABELA as an Early Diagnostic Marker for Sepsis-associated Acute Kidney Injury.
NCT06001294 ·Status: UNKNOWN
-
Biomarkers for the Early Identification of Sepsis in the Emergency Department
NCT02707718 ·Status: COMPLETED
-
Regulation of Endocrine, Metabolic, Immune and Bioenergetic Responses in Sepsis
NCT00187824 ·Status: UNKNOWN
-
Comparison the Value of Several Biomarkers of Sepsis
NCT01388725 ·Status: COMPLETED
-
The Early Coagulopathy for the Prognosis in Sepsis
NCT04582188 ·Status: UNKNOWN
-
Dynamic Alterations of Th2/Th1 With New Onset of Community-acquired Severe Sepsis Patients
NCT02883218 ·Status: COMPLETED
-
Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis
NCT06626984 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis
NCT05640037 ·Status: COMPLETED
-
TRIM25 in Septic Patients
NCT07320638 ·Status: ENROLLING_BY_INVITATION
-
Use of Fc-MBL to Detect and Monitor the Presence of PAMPs During Septic Shock
NCT03457038 ·Status: UNKNOWN ·Phase: NA
-
Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis
NCT05229328 ·Status: UNKNOWN
-
Alterations of Immunologic Mediators During Severe Sepsis
NCT00484146 ·Status: TERMINATED
-
Comparison Between the Progostic Value of the Procalcitonin and the Platelet/Total Leukocytic Count Ratio in Sepsis
NCT06991686 ·Status: COMPLETED
-
Defining Circulating Micro-RNA Biomarkers for the Early Diagnosis and Prognosis of Sepsis
NCT02544490 ·Status: COMPLETED
-
Early Vasopressors in Sepsis
NCT05179499 ·Status: RECRUITING ·Phase: PHASE3
-
Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient
NCT04105400 ·Status: UNKNOWN
-
The Effect and Mechanism of lncRNA NBR2 Regulating Endothelial Pyroptosis by Targeting GSDMD in Sepsis
NCT04427371 ·Status: UNKNOWN